Compassionate Use of Ibalizumab for the Treatment of HIV Infection

Summary

Ibalizumab is a humanized immunoglobulin G monoclonal antibody directed against a human T-cell receptor (CD4) and thus suppresses HIV replication by blocking entry of HIV into CD4+ lymphocytes. Ibalizumab has completed phase I and II clinical studies in HIV-negative and HIV-infected individuals showing safety and efficacy for suppressing HIV replication.

Timeline

Start

2012-01

Primary completion

2014-02

Completion

2014-02

Drugs

Indications